A Prospective Study of the Kidney Protective Effect of Aliskiren in Hypertensive Patients With IgA Nephropathy
Lead SponsorKagawa University
Indication/ConditionGlomerulonephritis, IGA Hypertension
The purpose of this study is to evaluate the effect of aliskiren, a novel direct rennin inhibitor, on renal function and progress of renal disease in hypertensive patients with IgA nephropathy.
Inclusion Criteria: IgA nephropathy confirmed by renal biopsy Hypertension (<= 125/75 mmHg) Exclusion Criteria: Patients who have been treated with angiotensin type 1 receptor blocker or angiotensin-converting enzyme inhibitor within 4 weeks Severe hypertension (<= 180/110 mmHg) or secondary hypertension Patients with history of allergy or adverse effect for aliskiren Renal dysfunction (estimated Glomerular Filtration Rate < 60 mL/min/1.73m2) Pregnancy Patient treated with cyclosporine Hyperkalemia (serum potassium >= 5.6 mmol/L) Autoimmune disease including systemic lupus erythematosus Patients inadequate for the study